---

---

publishing date : 2020 - 12 - 10    tags : Trial   

save search

---

UFP Industries announces agreement to acquire PalletOne, further expanding industrial packaging capabilities in the U.S.
Published: 2020-12-10 (Crawled : 21:06) - globenewswire.com
UFPI 4 | $112.68 0.8% 0.79% 380K |

Non-Energy Minerals

| 109.96% | O: 0.06% H: 3.12% C: 0.91%
trial

---

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis
Published: 2020-12-10 (Crawled : 21:02) - globenewswire.com
PASG | News | $1.15 0.0% 84K |

Health Technology

| -95.91% | O: -3.05% H: 3.7% C: 1.67%
trial treatment authorized

---

REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2020-12-10 (Crawled : 18:00) - biospace.com/
RGNX | $15.68 -0.06% -0.06% 440K |

Health Technology

| -59.83% | O: -0.28% H: 4.02% C: 0.08%
liver trial diabetic treatment diabetes

---

Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
Published: 2020-12-10 (Crawled : 16:01) - biospace.com/
FUSN | $21.325 0.31% 0.3% 350K |

Health Technology

| 76.49% | O: 0.0% H: 5.38% C: 3.31%
trial phase 3 phase 1 phase 2 solid tumors

---

Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
HOTH | $1.21 1.21% 1.2% 15K |

Health Technology

| -30.3% | O: 4.24% H: 16.28% C: 6.98%
dermatitis trial approval treatment atopic dermatitis phase 1b phase 2b

---

Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
HEPA | $1.45 -27.86% -38.62% 320K |

Health Technology

| -15.06% | O: -3.01% H: 18.63% C: 12.42%
trial nash phase 2b crv431

---

TG's New Drug Outshines Sanofi's Aubagio in MS Phase III Trial
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M |

Health Technology

| -6.72% | O: -0.22% H: 0.85% C: 0.48%
drug trial new drug

---

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal TrialCompany Expects Interim Data in Mid-2021
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
TCON | $1.8 -8.16% -8.89% 140K |

Health Technology

| -76.05% | O: -2.98% H: 10.13% C: 7.28%
trial

---

Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
GERN | $3.73 1.08% 1.07% 8.2M |

Health Technology

| 116.86% | O: 2.33% H: 1.07% C: -0.85%
risk phase 3 trial merge enroll milestone

---

INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
INO | $10.005 3.36% 3.25% 330K |

Health Technology

| -12.34% | O: -0.91% H: 0.92% C: 0.3%
covid china vaccine trial phase 2 ino-4800

---

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
Published: 2020-12-10 (Crawled : 14:00) - biospace.com/
NVCR | $11.82 -2.23% -2.28% 810K |

Health Technology

| -92.65% | O: -0.71% H: 7.13% C: 5.19%
therapy radiation therapy phase 3 trial enroll glioblastoma

---

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
Published: 2020-12-10 (Crawled : 13:06) - globenewswire.com
TCON | $1.8 -8.16% -8.89% 140K |

Health Technology

| -76.05% | O: -2.98% H: 10.13% C: 7.28%
trial

---

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K |

Health Technology

| -97.24% | O: 4.43% H: 6.71% C: -1.41%
trial phase 3 phase 1 phase 2 enroll

---

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BYSI | $2.11 10.47% 9.48% 64K |

Health Technology

| -80.13% | O: 0.75% H: 4.39% C: 1.31%
breast cancer cancer positive results phase 3 trial trial results symposium

---

Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
Published: 2020-12-10 (Crawled : 13:01) - globenewswire.com
SPRO | $1.405 0.36% 0.36% 290K |

Health Technology

| -91.87% | O: -2.02% H: 1.88% C: 0.18%
disease trial phase 2b

---

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Published: 2020-12-10 (Crawled : 06:00) - biospace.com/
PBYI | $5.17 3.19% 3.09% 270K |

Health Technology

| -51.04% | O: 1.7% H: 1.4% C: -0.33%
biotech trial

---

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.78 174.71% 63.6% 72M |

AGBA | $2.565 105.2% 51.27% 200M |

Finance

MLEC | $2.44 74.29% 42.62% 78M |

n/a

EDBL | News | $6.28 67.02% 40.13% 16M |

ATGL | $2.91 48.81% 32.8% 180K |

ZAPP | $0.2175 47.16% 32.05% 16M |

n/a

ONFO | $0.6075 38.38% 27.74% 7.3M |

n/a

VIVK | $1.48 38.32% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.8M |

SDIG A | $3.635 35.13% 26.0% 1M |

---

Your saved searches

---